Hans Hammers
University of Texas Southwestern Medical Center
H-index: 61
North America-United States
Top articles of Hans Hammers
Abstract CT099: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation
Cancer Research
2024/4/5
Abstract LB257: Possible involvement of PDL1 intrinsic signaling to acquired resistance to immunotherapy for renal cell carcinoma (RCC)
Cancer Research
2024/4/5
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled …
2024/2/1
Nivolumab plus ipilimumab (NIVO+ IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate …
2024/2/1
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune …
2024/2/1
Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune …
2024/2/1
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).
2024/2/1
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023
The Oncologist
2024/2/1
Bryan Lewis
H-Index: 19
Hans Hammers
H-Index: 42
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Scientific reports
2024/1/17
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Journal for Immunotherapy of Cancer
2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
The Journal of Clinical Investigation
2024/4/23
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
New England Journal of Medicine
2024/4/18
Howard Gurney
H-Index: 33
Tian Zhang
H-Index: 1
Ajjai Alva
H-Index: 29
Hans Hammers
H-Index: 42
Hiroshi Kitamura
H-Index: 5
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
European Journal of Cancer
2024/4/8
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in …
2023/6/1
PD43-05 IMMUNOMODULATORY RESPONSE TO NEOADJUVANT NIVOLUMAB IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: RESULTS FROM a PHASE I TRIAL
The Journal of Urology
2023/4
Communicating a Diagnosis of RCC to Patients.
Cancer Network
2023/3/21
Hans Hammers
H-Index: 42
Treatment for RCC: Educating Patients on Followup and Adverse Events.
Cancer Network
2023/3/21
Hans Hammers
H-Index: 42
Healthcare Professional Perspectives on Diagnosing RCC.
Cancer Network
2023/3/21
Hans Hammers
H-Index: 42
Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.
2023/2/20
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).
2023/2/20
